PHILADELPHIA, 21 June 2010 – ERT, a global provider of technology and services to the pharmaceutical, biotechnology and medical device industries, announced today the availability of a new report, conducted by the Tufts Center for the Study of Drug Development, mapping the growing adoption of centralized ECG (electrocardiogram) services. The industry-wide report measures the current and anticipated adoption levels of centralized ECGs in clinical trials. This document, entitled “Mapping Adoption of Centralized Cardiac Safety Assessment,” is available to download from the company’s Centralized Cardiac Safety microsite – www.ert.com/ecg.
The new study, supported by an unrestricted grant from ERT, focuses on the use and adoption of digital and electronic ECGs and reports industry perceptions regarding the use of a centralized cardiac safety assessment provider in support of clinical studies. While the study reported only 33% of respondents currently use a centralized ECG approach, 89% of respondents expect the use of centralized ECGs to increase in five years. The significant increase in centralization is anticipated due to regulatory pressures and sponsors’ needs to provide high quality data being highlighted as the key factors to drive significant adoption.
The results confirm that respondents feel that centralized core labs are a valuable way of conducting cardiac safety assessments and most executives that were interviewed believe that 100% of all cardiac safety studies will eventually be handled by centralized providers. Ninety-seven percent of respondents rated central labs as being more accurate, and 90% rated them as being more efficient than a decentralized approach. Despite the reluctance to deviate from using a decentralized approach due to financial concerns, the Tufts report demonstrates that perceptions are changing with 70% of respondents rating the costs of using an ECG core lab to be less than, or equal to, the cost of using paper. The study further highlights integrating data and workflows into a core lab can result in improved patient safety, increased productivity, allow faster database locks, enhanced service, greater satisfaction and potential cost savings, all of which are offered by a centralized approach. The study also examines the challenges of traditional decentralization methods.
Mike McKelvey, CEO at ERT, comments, “The study by the Tufts Center for the Study of Drug Development highlights the growing adoption of centralization as our sponsors are realizing the need for and benefits of a core ECG laboratory. Currently approximately 33% of clinical trials use a centralized core lab for cardiac safety; we anticipate that this will increase in the short- and long-term. Regulatory pressures and the necessity for better data quality and accuracy at a faster and more efficient speed are stimulating more rapid adoption. With more accurate, higher quality and standardized data at a lower cost, the positive benefits of centralization are now much better understood by industry professionals.”
The report, examining how central core laboratories are playing an increasingly important role in cardiac safety during clinical trials, is available to download on www.ert.com/ecg.
For further press information, please contact Fiona Robinson, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire, CW4 8AA, United Kingdom.
Phone +44 1477 539539, Fax +44 1477 539540, Email email@example.com.
Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/) is a global provider of technology and services to the pharmaceutical, biotechnology and medical device industries. The Company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development and centralized respiratory technology and services to evaluate pulmonary function efficacy and safety in clinical development. The Company also provides solutions to streamline the clinical trials process by enabling its customers to automate the collection, analysis, and distribution of ePRO clinical data using multi-mode technology in all phases of clinical development as well as selected medical devices for the clinical trials and healthcare industries.
Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties, which could cause actual results to differ materially from those expressed or implied from such statements. These risks and uncertainties include, without limitation, the Company's ability to obtain new contracts, variability in size, scope and duration of projects, integration of acquisitions, competitive factors, technological development, market demand, and other factors described in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
The Scott Partnership
Tel: +44 1477 539539
+1 215 972 0420